Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Prokidney (PROK) Shares Outstanding (Diluted Average) (2022 - 2025)

Prokidney (PROK) has disclosed Shares Outstanding (Diluted Average) for 4 consecutive years, with $133.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 36.79% to $133.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $133.9 million through Dec 2025, up 36.79% year-over-year, with the annual reading at $133.9 million for FY2025, 36.79% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $133.9 million at Prokidney, down from $135.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $135.0 million in Q3 2025, with the low at $6.2 million in Q2 2022.
  • Average Shares Outstanding (Diluted Average) over 4 years is $84.6 million, with a median of $64.6 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) soared 932.82% in 2023, then decreased 0.96% in 2024.
  • Over 4 years, Shares Outstanding (Diluted Average) stood at $61.5 million in 2022, then grew by 0.28% to $61.7 million in 2023, then skyrocketed by 58.66% to $97.9 million in 2024, then skyrocketed by 36.79% to $133.9 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $133.9 million, $135.0 million, and $130.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.